English 
Japanese 
January 13, 2023
New study by PRISM Biolab demonstrates rational design of small molecule inhibitors of CTLA-4 and B7-1 protein-protein interaction utilizing only a sequence of a binding peptide
The paper published in the special issue of Pharmaceuticals journal dedicated to “Small Molecules Targeting Protein-Protein...
Read More
October 31, 2022
Pharma Intelligence Award Japan 2022 Commemorative Webinar “PPI Inhibition by Small Molecules: A New Drug Discovery Paradigm”
PRISM BioLab's proprietary drug discovery platform, PepMetics®, is a technology that enables the control of protein-protein...
Read More
September 1, 2022
PRISM Biolab Wins Biotech Company of the Year Award of Informa Pharma Intelligence Award 2022
We are pleased to announce that we have won the Biotech company of the year in...
Read More
January 4, 2022
PRISM BioLab, enters multi-project drug discovery collaboration with Roche and Genentech
TOKYO, Japan, 5th Jan. 2022: -- PRISM BioLab, a Japan based biotechnology company with a proprietary...
Read More
November 1, 2021
The CREB-binding protein (CBP)/β-catenin inhibitor E7386, co-created by Eisai and PRISM BioLab, achieved the clinical POC (Proof of Concept)
Eisai Co., Ltd. and PRISM BioLab Co., Ltd. announced today that the CREB-binding protein (CBP) /...
Read More
November 1, 2021
PRISM BioLab raised 100 million yen in Series C funding from Eisai
PRISM BioLab, the Japan based biotechnology company with proprietary small molecule drug discovery technology ”PepMetics®”, today...
Read More
October 28, 2021
The paper of peptidomimetics is published in ACS Omega
This paper presents the new method to analyze how peptidomimetics scaffold mimic the actual peptide, and PRISM’s scaffold advantage is confirmed.
Visualized and Quantitative Conformational Analysis of Peptidomimetics
ACS omega, 6(40), 26601-26612 (2021)
Read More
Visualized and Quantitative Conformational Analysis of Peptidomimetics
ACS omega, 6(40), 26601-26612 (2021)
September 9, 2021
PRISM BioLab raised 1.3 billion yen in Series C funding
PRISM BioLab, the Japan based biotechnology company with proprietary small molecule drug discovery technology ”PepMetics®”, today...
Read More
June 16, 2021
Servier and PRISM BioLab enter drug discovery collaboration for a novel target
PRISM BioLab provides PepMetics® (peptide mimetic small molecules) Technology for generating Hit and Lead compounds against...
Read More
November 4, 2020
PRISM Biolab and Merck enter multi-project drug discovery collaboration
PRISM Biolab provides The PRISM Library, proprietary library of peptide mimetic small molecules for screening against...
Read More